Are We Ready for Routine Clinical Genomics in Cardiovascular Disease?

The use of genetic testing in healthcare is becoming increasingly relevant, especially in the field of cardiovascular disease. While current cardiology guidelines include recommendations for the incorporation of genetic testing, its adoption into clinical practice remains limited.

In this webinar, David Lanfear, advanced heart failure and transplant cardiologist, and Denise Perry, genetic counselor, will discuss current and future applications of genetics in healthcare. They will share practical considerations for integrating genetic testing into clinical and laboratory workflows, focusing on test development and initial findings from the CardioSeq clinical trial, which created a novel testing platform and assessed the clinical impact of a pragmatic clinical whole-genome sequencing test.

Learning Objectives 

• Understand current clinical guidelines for genetic testing in cardiology
• Identify common barriers for the implementation of real-world adoption of genetic testing in cardiology
• Learn about a clinical whole-genome sequencing test developed and deployed by Illumina Laboratory Services, designed to aid in the molecular diagnosis and risk assessment for cardiovascular disease
• Review the preliminary findings of the CardioSeq clinical trial

Speakers:

David E. Lanfear, MD, MS, FAHA, FACC, FHFSA
Chief Scientific Officer, Vice President of Research, Henry Ford Health, Professor of Medicine, WSU-SoM, MSU-CHM

David Lanfear is chief scientific officer and system vice president of research at Henry Ford Health. He is also a practicing advanced heart failure and transplant cardiologist and clinician-scientist who codirects the Center for Individualized and Genomic Medicine Research (CIGMA). His research focuses on precision medicine and genomics, and he has extensive experience in investigator-initiated and multicenter clinical trials in heart failure. Lanfear has been continuously funded by the NIH for his entire career and has produced nearly 200 published manuscripts, reaching high-impact journals including JAMA, NEJM, and Nature Medicine. He is nationally recognized in academic medicine, serving previously on the HFSA Board of Directors and ACC Heart Failure and Transplant Committee. He currently serves on the AHA Genomics and Precision Medicine leadership committee and chairs the HFSA Scientific Statements Committee. He is a standing member of an NIH grant review panel (CCHS), an associate editor at Circulation: Heart Failure, and serves on the editorial boards of JACC: Heart Failure, Heart Failure Reviews, JACC:Cardio-Oncology, and JACC: Basic to Translational Science.

Denise L. Perry, MS, CGC
Sr Director, Medical Genomics Lab Services, Illumina Lab Services, Illumina

Denise Perry is a board-certified genetic counselor with a passion for empowering patients with answers about the genetic causes of their medical conditions, with a specific focus on rare disease, cardiovascular disease, and cancer. At Illumina Laboratory Services (ILS), an accredited clinical laboratory at Illumina, she leads a team of genetic counselors, clinical genomics scientists, and laboratory directors dedicated to advancing the clinical applications of genomics. She and her colleagues at ILS work toward bridging Illumina’s genomic technologies with real-world patient care, helping to accelerate Illumina’s customer’s goals and the adoption of clinical genomics applications globally. Over the course of Perry’s career, her work across patient care, clinical translational research, and clinical laboratory operations has centered on understanding the delivery, impact, and outcomes of communicating clinically relevant genetic information to patients and their physicians. Perry and her team have been actively involved in the broader clinical genetics community, contributing to peer-reviewed publications and shaping industry best practices.